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Abstract
Background: Transcription factor-mediated reprogramming can efficiently convert differentiated cells into induced
pluripotent stem cells (iPSCs). Furthermore, many cell types have been shown to be amenable to reprogramming
into iPSCs, such as neural stem cells, hematopoietic progenitor and stem cells (HPC/HSCs). However, the
mechanisms related to the amenability of these cell types to be reprogrammed are still unknown.
Methods: Herein, we attempt to elucidate the mechanisms of HPC/HSC reprogramming using the sequential
reprogramming system that we have previously established.
Results: We found that HPC/HSCs were amenable to transcription factor-mediated reprogramming, which yielded
a high frequency of fully reprogrammed HPC/HSC-iPSCs. Genome-wide gene expression analyses revealed select
down-regulated tumor suppressor and mesenchymal genes as well as up-regulated oncogenes in HPC/HSCs
compared with mouse embryonic fibroblasts (MEFs), indicating that these genes may play important roles during
the reprogramming of HPC/HSCs. Additional studies provided insights into the contribution of select tumor
suppressor genes (p21, Ink4a and Arf) and an epithelial-to-mesenchymal transition (EMT) factor (Snail1) to the
reprogramming process of HPC/HSCs.
Conclusions: Our findings demonstrate that HPC/HSCs carry unique cellular characteristics, which determine the
amenability of HPC/HSCs to be reprogrammed into high-quality iPSCs.
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Background
The ectopic expression of a set of transcription factors, in-
cluding Oct4, Sox2, Klf4, and c-Myc (OSKM), has been
shown to convert somatic cells into induced pluripotent
stem cells (iPSCs) [1]. The generation of iPSCs has tre-
mendous therapeutic potential for making patient-specific
iPSCs available [2–4]. To date, many types of cells, includ-
ing embryonic fibroblasts, hepatocytes, gastric epithelial
cells, adult tail-tip fibroblasts (TTFs), pancreatic cells,
neural stem cells, B lymphocytes, T lymphocytes, and
trophoblast stem cells, have been successfully converted
into iPSCs [5–11]. In addition, iPSCs are indistinguishable
from embryonic stem cells (ESCs) with respect to global
transcription and epigenetic modifications and can
achieve pluripotency. These findings have led to enthusi-
asm for conducting proof-of-principle safety evaluations
for the therapeutic use of iPSCs [12–15]. The availability
of high-quality iPSCs is a prerequisite for their potential
therapeutic use.
During the reprogramming process, the epigenetic
transition from starting cells to pluripotent cells can be
achieved when cells reach an acquired pluripotency state
[16]. Accumulating evidence suggests that the dynamics
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of nuclear reprogramming may be diverse; a typical
example can be found in the reprogramming of B lympho-
cytes [8, 9]. Many studies have established that substitutes
for the traditional four reprogramming factors, now
known as “Yamanaka factors”, can be used to induce pluri-
potency [17, 18], indicating the complexity of the versatile
reprogramming process. Likewise, many developmental
events, such as the mesenchymal-to-epithelial transition
(MET), have also been found to coincide with the nuclear
reprogramming process [19]. The Ink4a/Arf locus, which
encodes three tumor suppressor genes (p16Ink4a and
p19Arf from Cdkn2a and p15Ink4b from Cdkn2b), was
found to be a barrier to reprogramming [20, 21], further
emphasizing the relationship between immortalization
and reprogramming. Furthermore, a negative correlation
has been revealed between excessive cell proliferation and
reprogramming efficiency in human somatic cells [22].
Therefore, understanding the molecular events of repro-
gramming in different cell types to elucidate the core cir-
cuit of nuclear reprogramming may allow more effective
interventions for the reprogramming of cells.
Hematopoietic cells belong to a well-defined popula-
tion of cells that have been rigorously defined based on
the expression of cluster of differentiation (CD) mole-
cules. These cells have been used widely in nuclear
transfer-mediated and transcription factor-mediated cell
reprogramming studies [10, 23]. One of the most not-
able breakthroughs in nuclear transfer-mediated repro-
gramming was carried out in terminally differentiated B
and T lymphocytes [24], supporting the notion that the
presence of residual adult stem cells in tissues does not
account for the observed successful reprogramming of
mammalian somatic cells [25]. Compared with somatic
cells, the epigenetic state of neural stem cells has been
proven amenable to nuclear reprogramming [7]. Add-
itionally, hematopoietic progenitor and stem cells (HPC/
HSCs) were found to be susceptible to transcription
factor-mediated reprogramming [10]. However, the
mechanisms related to the amenability of HPC/HSCs to
be reprogrammed remain unknown.
Herein, we attempt to determine the mechanisms re-
lated to the amenability of HPC/HSCs to be repro-
grammed by testing the potential of HPC/HSCs to be
reprogrammed into high-quality iPSCs using our previ-
ously established sequential reprogramming system [26]
and performing genome-wide gene expression analyses to
determine the underlying events correlated with HPC/
HSC reprogramming. Our results demonstrated that the
downregulation of select tumor suppressor genes and an
epithelial-to-mesenchymal transition (EMT) factor as well
as the upregulation of oncogenes in HPC/HSCs undergo a
unique reprogramming process through which HPC/
HSCs are amenable to be reprogrammed into iPSCs. Fur-
ther studies showed that tumor suppressor genes (p21,
Ink4a, and Arf) and an EMT factor (Snai1 1) participated
in the reprogramming of HPC/HSCs, in which independ-
ent ectopic activation of p21, Ink4a, Arf, and Snail1 along




The protocols of all animal experiments were approved by
the Animal Care and Use Committee of the National In-
stitute of Biological Sciences, Beijing, China. All animal
procedures were performed according to the National In-
stitute of Biological Sciences Guide for the Care and Use
of Laboratory Animals.
Isolation of HPC/HSCs
HPC/HSCs were isolated from tetraploid-complementation
(4N) mice derived from mouse embryonic fibroblasts
(MEFs) with a 129S2/Sv genetic background and a Rosa26-
M2rtTA transgene [27]. In the isolation procedure, the 4N
mice were euthanized, after which the tibia and femur were
dissected from both legs and maintained in ice-cold PBE
(phosphate-buffered saline (PBS) containing 0.5 % bovine
serum albumin and 2 mM ethylenediamine tetraacetic
acid). The muscles were removed from the bones using
sharp surgical scissors; a 5 ml syringe containing ice-cold
PBE was then inserted into one end of the bone, and the
bone marrow was extruded into a 5 ml tube. After thor-
ough mixing of the cell suspension, the cells were passed
through a 70 μm nylon mesh filter into a fresh 5 ml tube to
remove any cell clumps. The cell suspension was centri-
fuged at 300 × g for 10 minutes at 4 °C, the supernatant
was discarded, and the cell pellet was resuspended in 80 μl
PBE per 108 total cells. Then, 20 μl of CD117 MicroBeads
(Miltenyi, Bergisch Gladbach, Germany) was added to the
cell suspension and incubated on ice for 15 minutes. The
cells were washed twice with PBE in a final volume of
500 μl. Finally, the cell suspension was transferred to a
PBE-pretreated MS column (Miltenyi, Bergisch Gladbach,
Germany) under a magnetic field (MACS; Miltenyi, Ber-
gisch Gladbach, Germany), and the magnetically labeled
cells were flushed into PBE. The nucleated cells were cen-
trifuged at 500 × g for 10 minutes.
Flow cytometry
HSC/HPCs isolated by MACS were incubated with APC-
CD117 (c-kit; eBioscience) and FITC-CD45.2 (eBioscience,
San Diego, CA) and analyzed using LSR II (BD Biosciences,
San Jose, CA) as described previously [28]. Flow cytometric
analysis was performed for the cell proliferation rate using
BD Pharmingen™ BrdU Flow Kits (BD Biosciences, San
Jose, CA) according to the manufacturer’s instructions.
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Generation of HPC/HSC-iPSCs and cell culture
The generation of HPC/HSC-iPSCs was performed under
the sequential reprogramming system we established [26].
In detail, 5 × 104 HPC/HSCs were transferred to 3.5 cm
dishes with ES medium containing 50 ng/ml murine stem
cell factor (SCF; Peprotech, Rocky Hill, NJ), 10 ng/ml
murine interleukin (IL)-3 (Peprotech, Rocky Hill, NJ), and
10 ng/ml murine IL-6 (Peprotech, Rocky Hill, NJ).
Twenty-four hours later, the medium was replaced with
ES medium containing 1 μg/ml doxycycline (Dox; Sigma,
St. Louis, MO) to induce the expression of OSKM under
the regulation of tetracycline response elements (TRE).
Dox was removed on day 14. Two days after the with-
drawal of Dox, ESC-like colonies were picked and pas-
saged three days later to yield HPC/HSC-iPSCs. All ESCs
and iPSCs were cultured on mitomycin C-treated (Sigma,
St. Louis, MO) MEFs in ES medium, which consisted of
Dulbecco modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA) supplemented with 15 % fetal bovine serum
(FBS; Hyclone, South Logan, Utah), 1 mML-glutamine
(Invitrogen, Carlsbad, CA), 0.1 mM β-mercaptoethanol
(Invitrogen, Carlsbad, CA), 1 % nonessential amino acid
(Invitrogen, Carlsbad, CA), and 1000 U/ml leukemia in-
hibitory factor (LIF; Millipore, Darmstadt, Germany).
Quantitative PCR
We extracted mRNA using TRIzol (Invitrogen, Carlsbad,
CA) and reverse-transcribed the mRNA using M-MLV
reverse transcriptase (Promega, Madison, WI). Quantita-
tive PCR (Q-PCR) was carried out with SYBR Green-
based PCR Master Mix (Takara, Shiga, Japan). A total
volume of 20 μl containing 10 μl SYBR Green-based
PCR Master Mix, 0.2 mM dNTP, 0.2 μl forward primer
(10 mM), 0.2 μl reverse primer (10 mM), and 0.2 μl dye
II was mixed and plated for gene expression analyses
using the relative quantitation (RQ) of gene expression
of the Applied Biosystems 7500 Fast Real-Time PCR
System (Thermo Fisher Scientific, Waltham, MA) in ac-
cordance with the manufacturer’s instructions. One in-
dependent experiment contained three replicates of both
targeted genes and inner control. The results of three in-
dependent experiments in duplicate were averaged to
calculate the mean value of every gene. Relative expres-
sion levels of target genes in each cell line were normal-
ized to the level of their endogenous Gapdh. Paired
Student’s t tests were performed to assess the statistical
difference. The significant standard was set as: fold-
change >2; P <0.05. The primer pairs for real-time PCR
are summarized in Additional file 1: Table S1.
Alkaline phosphatase and immunofluorescence staining
Alkaline phosphatase (AP) staining was performed using
the Alkaline Phosphatase Detection Kit (Millipore, Darm-
stadt, Germany) according to the manufacturer’s
instructions. Immunofluorescence staining was performed
as described previously [29].
Teratoma formation
For the teratoma formation assay, iPSCs suspended in
PBS were injected subcutaneously into the forelimbs of
SCID mice. SCID mice were sacrificed 3 or 4 weeks after
the injection to collect the tumors, which were further
dissected for hematoxylin and eosin (H & E) staining to
identify the three germ layers.
Bisulfite genomic sequencing
Bisulfite genomic sequencing was conducted in triplicate
to analyze the DNA methylation of Pou5f1 and Nanog as
described previously [29]. The bisulfite PCR primer pairs
are summarized in Additional file 1: Table S1. The amp-
lified PCR products were cloned into a vector using the
pEASYTM-T5 Zero cloning kit (TransGen, Beijing,
China) and were sequenced by Invitrogen and Sangon-
Biotech (Sangon, Shanghai, China).
Generation of chimera and 4N mice
To generate chimera (2N) mice, 10–15 iPSCs were
microinjected into eight-cell stage ICR embryos using a
piezo-actuated microinjection pipette. The reconstructed
embryonic day 2.5 embryos were then transplanted into
the uteri of pseudo-pregnant mice. Tetraploid comple-
mentation was similarly performed using piezo-actuated
microinjection. The two-cell stage ICR embryos were
first electrofused into tetraploid embryos and cultured to
blastocysts. Then, 10–15 iPSCs were injected into the
cavum of the tetraploid blastocysts, which were then
transplanted into the uteri of pseudo-pregnant mice. A
cesarean section was performed at embryonic day 19.5,
and the resultant pups were fostered by lactating ICR
mothers.
Simple sequence length polymorphism
Primers for simple sequence length polymorphism
(SSLP) were selected according to the Mouse Genome
Informatics website (http://www.informatics.jax.org) and
performed as reported previously [26, 30].
Western blot
Whole cell extracts were prepared using RIPA buffer
and ultrasonic extraction, resolved on SDS-PAGE gels,
and transferred to polyvinylidene fluoride membranes.
Specific proteins were analyzed using anti-CDKN2A/
p16INK4a (Abcam, Cambridge, UK), anti-CDKN2A/
p19ARF (Abcam, Cambridge, UK), anti-SNAI1 (Millipore,
Darmstadt, Germany), and anti-Gapdh (Sigma, St. Louis,
MO). Enhanced chemiluminescence peroxidase-labeled
anti-mouse, rabbit or goat antibodies (Amersham, Pitts-
burgh, PA) were used for further detection.
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Gene construction and transient and stable transfection
The cDNAs of Ink4a, Arf, Ink4b, p21, and Snail1 were
cloned separately into the TetO-FUW plasmid, and the
reconstructed plasmids were transfected into 293T cells
along with lentivirus packaging plasmids ps-PAX-2 and
pMD2G. Viral supernatants were harvested 48 hours
after transfection, filtered through a 0.45 μm filter
(Millipore, Darmstadt, Germany), and concentrated by
centrifugation. HPC/HSCs from 4N mice were incubated
with virus resuspended in ES medium containing SCF, IL-
3, and IL-6 for 24 hours; the medium was then replaced
with ES medium containing 1 μg/ml Dox to access the re-
programming efficiency of specific candidate genes.
RNA sequencing
Total RNA was isolated from cell pellets using TRIzol
(Invitrogen, Carlsbad, CA). The RNA integrity was con-
firmed with a minimum RNA integrity number of 8 using
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
The mRNA was enriched using oligo(dT) magnetic beads
and sheared to create short fragments of ~200 base pairs.
cDNA was then synthesized using random hexamer
primers and purified using a PCR product extraction
kit (Qiagen, Germany). Finally, the sequencing primers
linked to the cDNA fragments were isolated by gel elec-
trophoresis and enriched by PCR amplification to con-
struct the library for sequencing. Single-end sequencing
was applied to RNA sequencing at the Beijing Genom-
ics Institute using the HiSeq™ 2000 system developed
by Illumina (Illumina, San Diego, CA). The RNA se-
quencing reads were mapped to the mouse genome
using Tophat (v1.3.3) and the Ensembl genome annota-
tion (Mus_musculus.NCBIM37.64.gtf ) with the default
parameters [31]. The fragments per kilobase of exon
per million fragments mapped (FPKM) for each gene
were calculated using Cufflinks (v1.2.0) [32]. Hierarch-
ical clustering was presented as mean ± standard devi-
ation (SD) based on two biological replicates to
describe the relationship among samples.
Statistical analyses
The SD was used to assess biological significance.
Accession numbers
The genome-wide gene expression data reported in this
article were deposited in Gene Expression Omnibus
[GEO:GSE36294].
Results
Derivation of high-quality iPSCs from HPC/HSCs
To determine the reprogramming potential of HPC/HSCs,
our sequential reprogramming system was used to gener-
ate the genetically identical iPSCs [26, 27] (Fig. 1a). HPC/
HSCs were isolated from 4N mice derived from 10-MEF-
iPSCs using MACS MicroBeads technology with a purity
of approximately 92 % when analyzed by flow cytometry
(Fig. 1b). The characteristics of the HPC/HSCs were veri-
fied by analyzing the expression of HPC/HSC-specific
genes (Additional file 2: Figure S1A). Exposure of the
freshly sorted HPC/HSCs to Dox and the addition of SCF,
IL-3, and IL-6 resulted in re-expression of the four tran-
scription factors (Oct4, Sox2, Klf4, and c-Myc) and rapid
proliferation. The suspended HPC/HSCs adhered to the
bottom of the culture dishes 3 days later, and the AP-
positive ESC-like colonies emerged approximately 9 days
after induction, much sooner than the control MEFs
(Fig. 1c, top). The average reprogramming efficiency of
HPC/HSCs was 1.1 % when measured by AP staining, ap-
proximately threefold greater than MEFs (Fig. 1c, bottom).
Two days following the withdrawal of Dox, transgene-
independent HPC/HSC-iPSC lines were established from
day 16 ESC-like colonies that displayed typical expression
patterns of pluripotency-related genes (Oct4, Sox2, and
SSEA-1; Additional file 2: Figure S1B). In addition, the
global expression patterns of HPC/HSC-iPSCs were in-
distinguishable from those of ESCs (Additional file 2:
Figure S1C). Bisulfite genomic sequencing results showed
that demethylation of Pou5f1 and Nanog occurred in
HPC/HSC-iPSCs (Additional file 2: Figure S1D). Notably,
Q-PCR results showed that the exogenous OSKM expres-
sions were silenced in HPC/HSC-iPSCs, which were well
maintained under the expression of endogenous pluripo-
tency genes (Additional file 3: Figure S2A). The in vivo
differentiation potential of HPC/HSC-iPSCs was further
confirmed by teratoma formation assays and three typical
embryonic germ layers were observed (Additional file 3:
Figure S2B). The birth of reconstructed 2N mice further
validated the chimeric and germline transmission poten-
tial of HPC/HSC-iPSCs (Additional file 3: Figure S2C).
To stringently evaluate the pluripotency state of HPC/
HSC-iPSCs, tetraploid complementation was performed
on the HPC/HSC-iPSCs and viable 4N mice were ultim-
ately generated (Fig. 1d). Healthy offspring were pro-
duced after the adult 4N mice were mated with female
ICR mice (Fig. 1d). To confirm the genetic background
of the 4N mice, SSLP analyses were performed. The
SSLP results indicated that the 4N mice were indeed
produced from HPC/HSC-iPSCs and that they had a
129/Sv ×M2rtTA genetic background (Fig. 1e). To the
best of our knowledge, this is the first demonstration
that viable, fertile 4N mice can be generated from HPC/
HSC-derived iPSCs.
Interestingly, a large proportion (5/9) of HPC/HSC-
iPSC lines gave rise to 4N mice (Fig. 1f and Additional
file 3: Figure S2C). Based on published results, the average
ratio of 4N competent iPSCs never exceeds 40 % [14, 33].
To exclude the possibility that the sequential reprogram-
ming system utilized here resulted in a large proportion of
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high-quality iPSCs, skin fibroblasts (SFs) and TTFs from
the same 4N mouse as the HPC/HSCs were used to
generate SF-iPSCs and TTF-iPSCs, respectively, and tetra-
ploid complementation was performed to test the pluripo-
tency of the derived cell lines. SF-iPSCs were found to
achieve a full pluripotency state with low proportion (1/6;
Additional file 4: Table S2). However, none of the TTF-
iPSC lines (0/4) supported the full development of 4N
mice (Additional file 4: Table S2). These results indicate
that HPC/HSCs are more amenable to reprogramming
into high-quality iPSCs than somatic cells.
Genome signatures of HPC/HSCs correlated with
accelerated reprogramming
As already mentioned, HPC/HSCs are amenable to re-
programming into high-quality iPSCs, suggesting that
the reprogramming process may be different in HPC/
HSCs compared with MEFs. Concerning the morph-
ology change of HPC/HSCs during the reprogramming
process, precolonies were observed 3 days post repro-
gramming which are similar to the control MEFs
(Additional file 5: Figure S3A). However, more com-
pact colonies, which are an indication of naive pluri-
potency, were derived from HPC/HSCs in the middle
and late stages of reprogramming when compared
with MEFs (Fig. 2a). However, the underlying mecha-
nisms of HPC/HSC reprogramming remain unclear.
To gain insight into the intrinsic events related to
HPC/HSC reprogramming, genome-wide gene expres-
sion analyses were performed in HPC/HSCs using MEFs
and pluripotent stem cells as controls. First, we com-
pared the global gene expression patterns from HPC/
HSCs, MEFs, R1(ESCs), and iPSCs (10-MEF-iPSC-37).
Principle component analysis (PCA) showed that HPC/
HSCs and MEFs demonstrated gene expression patterns
that differed from those of pluripotent stem cells, indi-
cating that dramatic cell fate transitions occurred during
the process of reprogramming (Fig. 2b). Next, HPC/
HSC-specific and MEF-specific genes were subjected to
gene ontology (GO) analysis; the results showed that
highly expressed genes in HPC/HSCs mainly correlated
with functions related to hematopoiesis (Fig. 2c). In
MEFs, genes that were highly expressed were associated
with extracellular matrix functions (Fig. 2d).
Previous studies have shown that epithelial cells can
be reprogrammed with a higher efficiency than MEFs
and that the induction of MET enhances reprogramming
efficiency [19, 34]. Moreover, ultrafast cycling cell popu-
lations were found to be privileged adopters of the pluri-
potency state, suggesting a role for the cell cycle in
reprogramming [35]. To investigate whether these two
events also affected the reprogramming of HPC/HSCs,
mesenchymal genes, epithelial genes, and cell cycle-
related genes were analyzed in HPC/HSCs, MEFs, ESCs,
and iPSCs. We found that the expression levels of mes-
enchymal genes (Zeb1, Snail1, Col1a1, Col5a1, Col6a1,
Itgbl1, and Thy1) were downregulated in HPC/HSCs
compared with MEFs, while epithelial genes (L1td1,
Ocln, Epcam, and Cdh1) demonstrated no changes
(Fig. 2e), suggesting that HPC/HSCs undergoing repro-
gramming might require fewer steps to switch off the
MET program compared with MEFs. Flow cytometric
analysis of 5-bromo-2′-deoxyuridine (BrdU) incorpor-
ation was performed on HPC/HSCs to assess cell prolif-
eration following the first 48 hours after reprogramming
using MEFs as the control. We found a higher number
of S-phase (BrdU+) cells in HPC/HSCs compared with
MEFs, indicating a rapid doubling of HPC/HSCs in the
first 48 hours after reprogramming (Additional file 5:
Figure S3B, C). Consistently, several tumor suppressor
genes among the cell cycle-related genes, including
Cdkn1a, Cdkn2a, Cdkn2b, and Rb1, showed lower expres-
sion patterns in HPC/HSCs than in MEFs, whereas onco-
genes, such as Myc and E2f2, were more highly expressed
in HPC/HSCs (Fig. 2e). Q-PCR results confirmed differen-
tial expression patterns for p21 (encoded by Cdkn1a), Ink4b
(encoded by Cdkn2b), Ink4a (encoded by Cdkn2b), Arf
(encoded by Cdkn2b), E2f2, Myc, Snail1, Col1a, and Col6a
between HPC/HSCs and MEFs (t test, P <0.05) (Fig. 2f).
Western blot further confirmed the differential expression
patterns of Snail1, Arf, and Ink4a (Fig. 2g) between HPC/
HSCs and MEFs. These results indicate the potential role
of these genes in HPC/HSC reprogramming.
The participation of select tumor suppressor genes and
an EMT factor in HPC/HSC reprogramming
To elucidate the mechanisms underlying HPC/HSC re-
programming, the functions of select cell cycle-related
(See figure on previous page.)
Fig. 1 Transcription factor-mediated reprogramming of HPC/HSCs results in high-quality iPSCs with full pluripotency. a Schematic showing the
generation of iPSCs from HPC/HSCs. b Flow cytometry analysis of the purity of HPC/HSCs isolated by MACS. First column, cells were isolated based
on size, as indicated by side scatter (SSC) and forward scatter (FSC). Second column, CD45-positive cells were further selected. Third column, c-Kit
and CD45 double-positive cells were isolated. c The reprogramming efficiency of HPC/HSCs was analyzed using AP staining. MEFs were used as
the control (n = 3 measurements). Error bars indicate the SD. **P <0.01, unpaired t test. d Viable 4N mice and the offspring (F1) of 4N mice
derived from HPC/HSC-iPSCs with the indicated cell line. e Genetic characterization of the 4N mice using SSLP analysis. f Summary of the
derivation of mice from HPC/HSC-iPSCs. #Karyotype was considered normal when greater than 80 %. Dox doxycycline, E19.5 embryonic day 19.5,
HPC/HSC hematopoietic progenitor and stem cell, iPSC induced pluripotent stem cell, MEF mouse embryonic fibroblast, 2N chimera, 4N tetraploid
complementation, ND not determined, OSKM Oct4, Sox2, Klf4, and c-Myc. APC Allophycocyanin, FITC Fluorescein isothiocyanate
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genes (p21, Ink4b, Ink4a, Arf, and E2f2) and an EMT
factor during reprogramming were studied. The kinetics
of p21, Ink4b, Ink4a, Arf, E2f2, and Snail1 expression
during the reprogramming process of HPC/HSCs and
MEFs were therefore analyzed for their potential func-
tions. We found that the tumor suppressor genes p21,
Ink4b, Ink4a, and Arf, as well as the EMT factor Snail1,
showed lower expression in the intermediate HPC/HSCs
than in the intermediate MEFs (t test, P <0.05), whereas
the oncogene E2f2 showed an opposite pattern (t test,
P <0.05), indicating the potential participation of these
genes in HPC/HSC reprogramming (Fig. 3a).
Independent ectopic activation of p21 (t test, P <0.05),
Ink4b (t test, P <0.05), Ink4a, Arf, and Snail1, along with
OSKM, was performed to characterize the functions of
these genes in HPC/HSC reprogramming (Fig. 3b, c).
The results showed that the overexpression of p21,
Ink4a, and Arf decreased the reprogramming efficiency
of HPC/HSCs, but the overexpression of Ink4b exhibited
no effect (Fig. 3d, e). Our observed roles of p21, Ink4a,
and Arf in HPC/HSC reprogramming were consistent with
previous reports [20, 21], suggesting that immortalization is
indispensable for the accelerated reprogramming of HPC/
HSCs. Similar to the tumor suppressor gene results, the
overexpression of Snail1 also decreased the efficiency of
HPC/HSC reprogramming (Fig. 3d, e), which is in ac-
cordance with a previous report [19]. Taken together,
these results indicate that select tumor suppressor
genes and an EMT factor participate in the repro-
gramming of HPC/HSCs.
Collectively, the work presented here showed that the
reprogramming of HPC/HSCs results in a high fre-
quency of high-quality iPSCs with full pluripotency.
Genome-wide analyses showed that the downregulation
of select tumor suppressor genes and an EMT factor and
the upregulation of select oncogenes occur in HPC/
HSCs, suggesting that these factors are potentially in-
volved in the amenability of HPC/HSCs to be repro-
grammed. Further exploration demonstrated that select
tumor suppressor genes (p21, Ink4a, and Arf ) and an
EMT factor (Snail1) participate in HPC/HSC repro-
gramming, in which independent ectopic activation of
p21, Ink4a, Arf, and Snail1 along with OSKM decreased
the reprogramming efficiency of HPC/HSCs (Fig. 4).
Discussion
In the present study, the mechanisms of reprogramming
HPC/HSCs into high-quality iPSCs were investigated by
a combination of techniques, including genome-wide
analysis. To our knowledge, this study is the first to
demonstrate that HPC/HSCs are amenable to be repro-
grammed into high-quality iPSCs with full pluripotency
at a high frequency. Through genome-wide analysis, we
selected several candidates and further verified their po-
tential contribution to HSC/HPC reprogramming. Fur-
thermore, we discovered that select tumor suppressor
genes (p21, Ink4a, and Arf ) and an EMT factor (Snail1)
participated in HPC/HSC reprogramming, suggesting
that both immortalization and EMT transition are indis-
pensable for HPC/HSC reprogramming.
The quality of iPSCs determines the biosafety of
cell transplantation-based regenerative medicine. Many
strategies have been used to improve the quality of iPSCs
[9, 14]. A previous study has shown an association be-
tween differentiation state and the reprogramming
efficiency of iPSCs [10]; however, the mechanisms corre-
lated with the amenability of HPC/HSCs to reprogram
into iPSCs have not been rigorously addressed. Moreover,
it is of significance to test whether increased reprogram-
ming efficiency can result in high-quality iPSCs with full
pluripotency. Our finding that a large proportion of HPC/
HSC-iPSCs show full pluripotency is comparable with
previous results which used the overexpression of Zscan4
during reprogramming [36]. The presence of a large pro-
portion of HPC/HSC-iPSCs with full pluripotency in our
study demonstrates the susceptibility of HPC/HSCs to re-
programming and, reciprocally, defines the notion that
different cell types face distinct barriers to achieve plur-
ipotency. Further elucidation of the mechanisms under-
lying somatic stem and progenitor cell reprogramming
will undoubtedly shed light on our understanding of the
4N competency of iPSCs.
The cellular states of starting cells have been shown to
have a great impact on the cellular reprogramming process
[7]. Furthermore, the acquisition of immortalization is
found to be a crucial and rate-limiting step in the establish-
ment of pluripotency [21]; in particular, the abro-
gation of Trp53 eliminates the roadblock in iPSC
cellular reprogramming [37, 38]. In addition, the
(See figure on previous page.)
Fig. 2 Genome-wide signature analyses reveal the unique characteristics related to HPC/HSC reprogramming. a Morphology differences during
the reprogramming process of HPC/HSCs and MEFs. Scale bar, 100 μm. b Principle component analysis of global gene expression patterns in
HPC/HSCs, MEFs, R1 ESCs, and iPSCs. The analysis of each cell line was based on two biological replicates. c Gene ontology (GO) of highly
expressed genes in HPCs/HSCs. d GO of highly expressed genes in MEFs. c, d X axis depicts the P value. e Gene expression analyses of
mesenchymal genes, epithelial genes, and cell cycle-related genes in HPC/HSCs and MEFs. The cluster analysis is presented as the mean ± SD
based on two biological replicates. f Comparison of expression analyses of indicated genes in HPC/HSCs and MEFs (n = 3 measurements). Error
bars indicate the SD. g Western blot comparing the levels of the indicated genes in HPC/HSCs and in MEFs. D day, HPC/HSC hematopoietic
progenitor and stem cell, iPSC induced pluripotent stem cell, MEF mouse embryonic fibroblast
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acquisition of immortalization through the suppression of
the Ink4a/Arf locus can accelerate iPSC reprogramming
[20, 21], which may help the cell bypass reprogramming
barriers represented by the typical P53 and Rb pathways.
In addition, recent data have shown that an ultrafast cyc-
ling cell population pre-existing among hematopoietic
progenitors displays privileged induced reprogramming
activity [35]. Furthermore, considerable evidence suggests
that the EMT factor Snail1 exerts dual effects which de-
pend on the induction of EMT in the early stage of
reprogramming and that of MET in the late stage of
reprogramming [39, 40]. Similarly, we show in the
present study that HPC/HSCs which demonstrate the
downregulation of select tumor suppressor genes and
Fig. 3 Participation of select tumor suppressor genes and an EMT factor in HPC/HSC reprogramming. a Kinetics of expression of indicated genes
in the OSKM-mediated reprogramming of HPC/HSCs and MEFs (n= 3 measurements). Error bars indicate the SD. b, c Ectopic activation of indicated genes
during the reprogramming process of HPC/HSCs. d AP staining results for ectopic activation of p21, Ink4b, Ink4a, Arf, and Snail1 in the OSKM-mediated
reprogramming of HPC/HSCs. e Reprogramming efficiencies of the indicated genotypes relative to wild-type (WT) in HPC/HSCs (n= 3 measurements).
Error bars indicate the SD. *P <0.05, **P <0.01, unpaired t test. D day, HPC/HSC hematopoietic progenitor and stem cell, MEF mouse embryonic fibroblast
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an EMT factor and the upregulation of oncogenes
could achieve pluripotency with high efficiency. Gene
function analyses showed that select tumor suppressor
genes and an EMT factor play important roles in
HPC/HSC reprogramming, a finding that is consistent
with previous reports [19, 20].
However, the efficiency of induced reprogramming ob-
served in the present study was lower than in previous
reports [10, 35]. This inconsistency may have resulted
from the different origins of the cells used in these stud-
ies as well as from differences in the technical details of
the reprogramming assay. The HPC/HSCs that were
used in the present study included myeloid progeni-
tors and HSCs. The major difference between these
two cell types is the cycling time, with HSCs being
slow cycling. In addition, the HPC/HSCs used here
were cultured in ES medium with SCF, IL-3, and IL-6
for 24 hours before exposure to Dox, a method that
may preferentially impact the proliferation of the ul-
trafast cycling population among the bulk cells.
Nevertheless, under the reprogramming conditions
used in the current study, high-quality iPSCs were
obtained from HPC/HSCs. Further investigation of
the reprogramming of HPC/HSCs will not only pro-
vide more information on the molecular barriers to
reprogramming but might also provide alternatives
that make it possible to overcome these inherent bar-
riers to achieving pluripotency. Finally, it will be in-
teresting to examine whether high-quality iPSCs can
be generated from progenitor cells derived from other
somatic tissues.
Conclusions
HPC/HSCs that exhibited a downregulation of select
tumor suppressor and mesenchymal genes and an up-
regulation of select oncogenes were amenable to tran-
scription factor-mediated reprogramming, which yielded
a high frequency of fully reprogrammed HPC/HSC-
iPSCs. Additional studies provided insights into the con-
tribution of select tumor suppressor genes (p21, Ink4a,
and Arf ) and an EMT factor (Snail1) to the amenability
of HPC/HSC reprogramming.
Additional files
Additional file 1: is Table S1 presenting the list of primers. (DOC 68 kb)
Additional file 2: is Figure S1 showing cellular characteristics and HPC/
HSC reprogramming. A Identification of HPC/HSCs using Q-PCR to detect
genes (Ikzf1, Lyl1, and Myb) specifically expressed by HPC/HSCs. MEFs,
adipose progenitor cells (APCs), and R1 ESCs were used as controls (n = 3
measurements). Error bars indicate the SD. B Expression of pluripotency-
related markers (Pou5f1, Sox2, and SSEA-1) detected by immunofluorescence.
DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI). C HPC/HSC-iPSCs
were indistinguishable from MEF-iPSCs at the level of global gene expression.
Cor Pearson correlation coefficient, X, Y log expression value. D Bisulfite
genomic sequencing of Pou5f1 and Nanog in HPC/HSC-iPSCs. R1 ESCs were
used as the control. Black circle methylated CpG; white circle unmethylated
CpG. (TIF 1727 kb)
Additional file 3: is Figure S2 showing silencing of OSKM factors and
the pluripotency state of HPC/HSC-iPSCs. A Q-PCR was used to detect
the gene expression levels of Pou5f1, Sox2, Klf4, and c-Myc in the indicated cell
lines. Gray column total; white column endogenous; red column exogenous.
Relative expression levels of these genes (Y axis) in each cell line were first
normalized to the level of their endogenous Gapdh, and then the amount
was normalized to R1 (n= 3 measurements). Error bars indicate the SD.
B) Hematoxylin and eosin (HE) staining of teratomas derived from iPSCs.
Ectoderm, lamellar corpuscle (×200); mesoderm, cartilage (×400); and
Fig. 4 Schematic illustration of the participation of select tumor suppressor genes (p21, Ink4a, and Arf) and an EMT factor (Snail1) in the
amenability of HPC/HSC reprogramming. Select tumor suppressor and mesenchymal genes were downregulated in HPC/HSCs and select
oncogenes were upregulated in HPC/HSCs compared with MEFs, indicating that these genes may play important roles in the reprogramming of
HPC/HSCs. The downregulation of tumor suppressor genes (p21, Ink4a, and Arf) and Snail1 in HPC/HSCs triggers the amenability of HPC/HSCs to
OSKM-mediated reprogramming. Independent ectopic activation of p21, Ink4a, Arf, and Snail1 along with OSKM decreases the efficiency of HPC/
HSC reprogramming. Dox doxycycline, HPC/HSC hematopoietic progenitor and stem cell, IL interleukin, MEF mouse embryonic fibroblast, 4N tetraploid
complementation, OSKM Oct4, Sox2, Klf4, and c-Myc, SCF stem cell factor
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endoderm, columnar epithelium and gland (×400). C viable 2N and 4N mice
derived from HPC/HSC-iPSCs with the indicated cell line. The placenta of each
newborn 4N mouse is displayed on the left of the 4N pup. (TIF 9159 kb)
Additional file 4: is Table S2 presenting characteristics of the SF-iPSCs
and TTF-iPSCs. (DOC 28 kb)
Additional file 5: is Figure S3 showing the cell morphology change and
cell proliferation rate of HPC/HSCs compared with MEFs. A The cell
morphology changes in the early reprogramming process of HPC/HSCs
and MEFs. Scale bar, 100 μm. B Flow cytometric analysis of BrdU/7-
Aminoactinomycin D (7-AAD) incorporation was performed on HPC/HSCs
during the first 48 hours after reprogramming to assess cell proliferation.
MEFs were used as the control. C Frequencies of cell cycle phases in the
early intermediate cells (48 hours after reprogramming) of HPC/HSC and
MEF populations (n = 3 measurements). Error bars indicate the SD.
*P <0.05, **P <0.01, unpaired t test. (TIF 2724 kb)
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